365997-32-6

Basic information

• Product Name: (1S,3R,4R)-ethyl 3-azido-4-hydroxycyclohexanecarboxylate
• Synonyms: (1S,3R,4R)-ethyl 3-azido-4-hydroxycyclohexanecarboxylate
• CAS NO: 365997-32-6
• Molecular Formula: C9H15N3O3
• Molecular Weight: 213.2337
• EINECS: -0
• Mol File: 365997-32-6.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (1S,3R,4R)-ethyl 3-azido-4-hydroxycyclohexanecarboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: (1S,3R,4R)-ethyl 3-azido-4-hydroxycyclohexanecarboxylate(365997-32-6)
• EPA Substance Registry System: (1S,3R,4R)-ethyl 3-azido-4-hydroxycyclohexanecarboxylate(365997-32-6)

Safety Data

• Hazardous Substances Data: 365997-32-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical and Medicinal Chemistry:
(1S,3R,4R)-ethyl 3-azido-4-hydroxycyclohexanecarboxylate is used as a precursor in the synthesis of pharmaceutical compounds for its potential medicinal properties. The hydroxycyclohexanecarboxylate moiety, which is similar to structures found in natural products and pharmaceuticals, lends itself to the development of new drugs with therapeutic benefits.
Used in Click Chemistry and Bioconjugation:
(1S,3R,4R)-ethyl 3-azido-4-hydroxycyclohexanecarboxylate is utilized as a reactant in click chemistry for its azido group, which allows for efficient and selective reactions with other molecules. This property is particularly useful in the field of bioconjugation, where it can be employed to attach biologically active molecules to various carriers or probes for research and diagnostic purposes.
Used in Chemical Synthesis:
In the chemical synthesis industry, (1S,3R,4R)-ethyl 3-azido-4-hydroxycyclohexanecarboxylate is used as an intermediate or building block for the creation of more complex organic molecules. Its unique structure and functional groups make it a valuable component in the synthesis of specialty chemicals and materials with specific properties.
Used in Research and Development:
(1S,3R,4R)-ethyl 3-azido-4-hydroxycyclohexanecarboxylate is employed as a research tool in academic and industrial laboratories. Its specific stereochemistry and functional groups make it an interesting subject for studies in organic chemistry, medicinal chemistry, and materials science, where it can be used to explore new reaction pathways, mechanisms, and applications.

Upstream product

• 75281-54-8 ethyl 7-oxabicyclo<4.1.0>heptane-3-carboxylate 
• 119719-61-8 (1R,4R,5R)-4-iodo-6-oxabicyclo[3.2.1]octane-7-one 
• 5709-98-8 (R)-cyclohex-3-enecarboxylic acid 
• 4771-80-6 1,2,5,6-tetrahydrobenzoic acid 
• 365997-31-5 (1S,3S,6R)-7-oxabicyclo[4.1.0]heptane-3-carboxylic acid ethyl ester 
• 932-67-2 cyclohex-3-enecarbonyl chloride 
• 15111-56-5 ethyl-3-cyclohexene-1-carboxylate 

Downstream Products

• 1255529-31-7 ethyl (1R,3S,4S)-3-((tert-butoxycarbonyl)amino)-4-((methylsulfonyl)oxy)cyclohexane-1-carboxylate 
• 1210348-23-4 C₁₄H₂₆N₂O₄ 
• 1210348-16-5 ethyl (1R,3S,4S)-3-((tert-butoxycarbonyl)amino)-4-hydroxycyclohexane-1-carboxylate 
• 915030-14-7 ethyl 4-hydroxy-3-[(trifluoroacetyl)amino]cyclohexanecarboxylate 
• 915030-15-8 ethyl 4-oxo-3-[(trifluoroacetyl)amino]cyclohexanecarboxylate 

Relevant articles and documents

Stereoselective synthesis and biological evaluation of 3,4-diaminocyclohexanecarboxylic acid derivatives as factor Xa inhibitors

There have been few reports on synthetic methods for cis-1,2-diaminocyclohexane bearing a third ring substituent. Starting from 3-cyclohexenecarboxylic acid, we developed efficient methods for synthesizing the 3,4-diaminocyclohexanecarboxylic acid derivat

INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR

Described herein are inhibitors of FGFR-4, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.

HETEROARYL COMPOUNDS AND USES THEREOF

The present invention relates to compounds useful as inhibitors of protein kinases, containing a cysteine residue in the ATP binding site. The invention further provides for pharmaceutically acceptable compositions comprising therapeutically effective amounts of one or more of the protein kinase inhibitor compounds and methods of using said compositions in the treatment of cancers and carcinomas.

Discovery of N-[(1R,2S,5S)-2-{[(5-chloroindol-2-yl)carbonyl]amino}-5-(dimethylcarbamoyl)cyclohexyl]-5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine-2-carboxamide hydrochloride: A novel, potent and orally active direct inhibitor of factor Xa

In the early 1990's, we reported on the low-molecular selective fXa inhibitor DX-9065a having two amidino groups. However, it had poor oral bioavailability due to its strong basic amidino groups. To obtain fXa inhibitors with improved oral bioavailability

2,3-SUBSTITUTED FUSED BICYCLIC PYRIMIDIN-4(3H)-ONES MODULATING THE FUNCTION OF THE VANILLOID-1 RECEPTOR (VR1)

The use of a compound of formula (I): for the manufacture of a medicament for the treatment of conditions ameliorated by the modulation of the function of the vanilloid-1 receptor (VR1, also known as TRPV1).

DIAMINE DERIVATIVES

A compound represented by formula (1):Q1-Q2-To-N(R1) -Q3-N(R2)-T1-Q4 [wherein R1 and R2 are hydrogen atoms or the like; Q1 is a saturated or unsaturated, 5- or 6- membered cyclic hydrocarbon group which may be substituted, or the like; Q2 is a single bond or the like; Q3 represents the following group: (wherein Q5 is an alkylene group having 1 to 8 carbon atoms, or the like); and T0 and T1 are carbonyl groups or the like], a salt thereof, a solvate thereof, or an N-oxide thereof. The compound is useful as an agent for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after artificial valve or joint replacement, thrombus formation and reocclusion after angioplasty, systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), thrombus formation during extracorporeal circulation, or blood clotting upon blood drawing.

Diamine derivatives

A compound represented by the general formula (1): Q1-Q2-T0-N(R1)-Q3-N(R2)-T1-Q4??(1) wherein R1 and R2 are hydrogen atoms or the like; Q1 is a saturated or unsaturated, 5- or 6-membered cyclic hydrocarbon group which may be substituted, or the like; Q2 is a single bond or the like; Q3 is a group in which Q5 is an alkylene group having 1 to 8 carbon atoms, or the like; and T0 and T1 are carbonyl groups or the like; a salt thereof, a solvate thereof, or an N-oxide thereof. The compound is useful as an agent for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after valve or joint replacement, thrombus formation and reocclusion after angioplasty, systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), thrombus formation during extracorporeal circulation, or blood clotting upon blood drawing.

DIAMINE DERIVATIVES

A compound represented by the general formula (1):Q1-Q2-T0-N(R1)-Q3-N(R2)-T1-Q4 wherein R1 and R2 are hydrogen atoms or the like; Q1 is a saturated or unsaturated, 5- or 6- membered cyclic hydrocarbon group which may be substituted, or the like; Q2 is a single bond or the like; Q3 is a group in which Q5 is an alkylene group having 1 to 8 carbon atoms, or the like; and T0 and T1 are carbonyl groups or the like; a salt thereof, a solvate thereof, or an N-oxide thereof. The compound is useful as an agent for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after valve or joint replacement, thrombus formation and reocclusion after angioplasty, systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), thrombus formation during extracorporeal circulation, or blood clotting upon blood drawing.

ETHYLENEDIAMINE DERIVATIVES

The invention relates a compound represented by the formula (1):Q1-Q2-C(=O)-N(R1)-Q3-N(R2)-T1-Q4 wherein R1 and R2 represent H or the like; Q1 represents an aromatic ring, heterocyclic ring or the like; Q2 represents a single bond, aromatic ring, heterocyclic ring or the like; Q3 represents a group or the like, Q4 represents an aromatic ring, heterocyclic ring or the like; and T1 represents -CO- or -SO2-, and a medicine which comprises the compound and is useful for thrombosis and embolism.

A new class of analogues of the bifunctional radiosensitizer α-(1-aziridinylmethyl)-2-nitro-1H-imidazole-1-ethanol (RSU 1069): The cycloalkylaziridines

A series of compounds related to α-(1-aziridinylmethyl)-2-nitro-1H-imidazole-1-ethanol (RSU 1069, 1) were synthesized and evaluated as selective hypoxic cell cytotoxic agents and as radiosensitizers. The aziridine moiety was replaced with a number of other potential alkylating groups including cycloalkylaziridines and azetidines. The data indicated that modification of the aziridine of 1 resulted in a substantial decrease in the ability of the compounds to selectively kill hypoxic cells. However, these modifications did not affect the compounds' in vitro radiosensitizing activity since many of the derivatives were as potent as 1. All of the compounds that were evaluated in vivo were less toxic than 1, and several members of this series had significant activity. The best compound was trans-α-[[(4-bromotetrahydro-2H-pyran-3-yl)amino]methyl]-2-nitro-1H- imidazole-1-ethanol (18), which, due to its activity and log P value, is a candidate for additional in vivo studies.